• 1
    Marfurt J, Nasereddin A, Niederwieser I, et al. Identification and differentiation of Leishmania species in clinical samples by PCR amplification of the miniexon sequence and subsequent restriction fragment length polymorphism analysis. J Clin Microbiol 2003; 41:31473153.
  • 2
    Marfurt J, Niederwieser I, Makia ND, et al. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis 2003; 46:115124.
  • 3
    Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995; 13:505523.
  • 4
    Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:15611577.
  • 5
    Ezzine Sebai N, Mrabet N, Khaled A, et al. Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases. Tunis Med 2010; 88:911.
  • 6
    Jeddi F, Caumes E, Thellier M, et al. Drug hypersensitivity syndrome induced by meglumine antimoniate. Am J Trop Med Hyg 2009; 80:939940.
  • 7
    Antezana G, Zeballos R, Mendoza C, et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992; 86:3133.
  • 8
    Ribeiro AL, Drummond JB, Volpini AC, et al. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz J Med Biol Res 1999; 32:297301.
  • 9
    Matoussi N, Ameur HB, Amor SB, et al. Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report. Med Mal Infect 2007; 37(Suppl 3): S257S259.
  • 10
    Castello Viguer MT, Echanove Errazti I, Ridocci Soriano F, et al. Torsade de pointes durante el tratamiento de la leishmaniasis con antimoniato de meglumina. Rev Esp Cardiol 1999; 52:533535.
  • 11
    Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100:264269.
  • 12
    Bouvresse S, Matichard E, Mahe E, et al. Symptomatic hypokalemia caused by meglumine antimoniate. Ann Dermatol Venereol 2007; 134:387388.
  • 13
    Poeppl W, Walochnik J, Pustelnik T, et al. Cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine. Am J Trop Med Hyg 2011; 84:562565.
  • 14
    Neub A, Krahl D, Stich A, Amon U. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges 2008; 6:10611064.
  • 15
    van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 2010; 50:8083.
  • 16
    Wysluch A, Sommerer F, Ramadan H, et al. The leishmaniasis—a parasite infection as differential diagnosis of malignant tumours of oral mucosa. A case report and review of literature. Mund Kiefer Gesichtschir 2007; 11:167173.
  • 17
    Richter J, Hanus I, Häussinger D, et al. Mucosal Leishmania infantum infection. Parasitol Res 2011; 109:959962.